Genvor Incorporated (GNVR)
| Market Cap | 25.12M +125,614,815.0% |
| Revenue (ttm) | n/a |
| Net Income | -3.45M |
| EPS | -0.10 |
| Shares Out | 36.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 0.6900 |
| Previous Close | 0.7000 |
| Day's Range | 0.6900 - 0.6900 |
| 52-Week Range | 0.0140 - 3.0000 |
| Beta | 537,225.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 10, 2026 |
About Genvor
Genvor Incorporated develops plant-based defense technology designed to help farmers achieve global food security. The company provides antimicrobial peptide technologies through the BioCypher platform by designing and validating minimum viable products and expanding its collaborations to include foliar application models, seed traits, and seed treatment platforms. The company has a strategic collaboration with Canlab International for the development, manufacturing, and commercialization of a portfolio of novel natural peptide candidates targe... [Read more]
Financial Performance
Financial StatementsNews
Genvor's Antimicrobial Peptides Advance into Sugar Beet Research
Woodland, CA, July 27, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR) (“Genvor”), a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across a...
Genvor Appoints Donald Kalkofen as Chief Financial Officer
Woodland, CA, May 21, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR) (“Genvor”), a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across ag...
Genvor Announces Strategic Memorandum of Understanding with Canlab International™ to Advance Commercial Peptide Pipeline
Woodland, CA, April 14, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR), a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture...
Genvor, Inc. Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026
CEO Chad Pawlak to deliver corporate update on AI-accelerated peptide platform and strategic growth initiatives WOODLAND, CA / ACCESS Newswire / March 5, 2026 / Genvor, Inc. (OTCQB:GNVR) ("Genvor" or ...
Genvor Announces Strategic Expansion into Health and Wellness Market, Leveraging Proprietary AI-Accelerated BioCypher Platform to Develop Consumer Peptide Solutions
Woodland, CA, March 04, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR), a biotechnology company harnessing AI to generate novel peptides that deliver high-performance solutions across agriculture...
Genvor's AGM182 Antifungal Peptide Technology Validated in Peer-Reviewed Publication in PhytoFrontiers™
Greenhouse trial results published jointly with USDA-ARS demonstrate 76-98% reduction in aflatoxin contamination in transgenic corn expressing the BioCypher-designed peptide AGM182 Greenhouse trial re...
Genvor Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization
Agricultural biologicals leader brings 15+ years of global R&D and product management experience from Syngenta to accelerate Genvor's strategic partnerships and market expansion Agricultural biologica...
Genvor to Present at the Life Sciences Virtual Investor Forum December 11th
WOODLAND, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced that Chad Pawlak, Chief Exec...
Genvor and Tuskegee University Announce Teaming Agreement to Advance Peptide Research and Sustainable Crop Protection Technologies
Woodland, CA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTC: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced it has entered into a formal teami...
Genvor Announces Issuance of New U.S. Patent for Corn with Antifungal Peptide
Woodland, CA, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCQB: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, announced today the United States Patent and Tra...
Genvor Restores Trading Status and Expands Global Collaborative Research Network
Woodland, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTCID: GNVR), a pioneer in AI-accelerated peptide technology for sustainable agriculture, today announced that it has regained active OTCQ...
Genvor to Unveil Latest Research on Patented Peptides for Aflatoxin Resistance in Corn at BioAgTech World Congress
Genvor's Research Enabled by R&D Agreement with USDA's Agricultural Research Service, Focused on Driving Solutions to the Nation's Most Pressing Agricultural Problems CHAPEL HILL, NC / ACCESSWIRE / Ap...
Genvor to Participate in BioAgTech World Congress in Raleigh, North Carolina
CHAPEL HILL, NC / ACCESSWIRE / April 2, 2024 / Genvor Incorporated (OTCQB:GNVR) ("Genvor" or the "Company"), a developer of sustainable plant health solutions leveraging patented peptides, today annou...
Genvor to Participate in World Agri-Tech Innovation Summit in San Francisco
Genvor Presenting as a Featured Startup at Leading Global AgTech Event CHAPEL HILL, NC / ACCESSWIRE / February 27, 2024 / Genvor Incorporated (OTCQB:GNVR) ("Genvor" or the "Company"), a developer of s...
Genvor to Attend BioSolutions Conference & Expo in Visalia, California
Genvor to Showcase Next-Generation Plant Health Solutions at Leading Industry Event CHAPEL HILL, NC / ACCESSWIRE / February 20, 2024 / Genvor Incorporated (OTCQB:GNVR) ("Genvor" or the "Company"), a d...
Genvor Provides Fiscal First Quarter 2024 Corporate Update
New CEO Appointment and OTCQB Venture Market Listing to Drive Commercialization Momentum Ahead of Planned FY25 Uplisting CHAPEL HILL, NC / ACCESSWIRE / February 15, 2024 / Genvor Incorporated (OTCQB:G...
Genvor Appoints Veteran Agribusiness Leader Chad Pawlak as Chief Executive Officer
Judith Miller to Transition to Chief Business Officer CHAPEL HILL, NC / ACCESSWIRE / January 17, 2024 / Genvor Incorporated (OTCQB:GNVR) ("Genvor" or the "Company"), a developer of sustainable plant h...
USDA and Genvor Scientists Publish Research Highlighting Broad-Spectrum Efficacy of Genvor's Antimicrobial Peptides
Paper Serves as Validation by USDA Scientists That Genvor AMPs are Highly Effective Against Harmful Fungi CHAPEL HILL, NC / ACCESSWIRE / December 18, 2023 / Genvor Incorporated (OTCQB:GNVR) ("Genvor" ...
Genvor Begins Trading on the OTCQB Venture Market
Innovative Developer of Sustainable Plant Health Solutions Enters the Public Markets CHAPEL HILL, NC / ACCESSWIRE / December 5, 2023 / Genvor Incorporated (OTCQB:GNVR) ("Genvor" or the "Company"), a d...
Genvor Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
CHAPEL HILL, NC / ACCESSWIRE / November 6, 2023 / Genvor Incorporated (OTCQB:GNVR) ("Genvor" or the "Company"), a developer of sustainable plant health solutions leveraging patented peptides, today an...